Disease · MONDO_0015759
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) vs Group C (Chemotherapy, Monoclonal Antibody Therapy): serious adverse events | 2 of 46 | 6 of 42 | 88 | NCT00057811 | Trial comparisons |
| Part A: PS-341 Alone vs Part B: PS-341 & EPOCH: serious adverse events | 21 of 24 | 40 of 44 | 68 | NCT00054665 | Trial comparisons |
| Part A: PS-341 Alone vs Part B: PS-341 & EPOCH: Number of Participants With Adverse Events | 23 of 23 | 44 of 44 | 67 | NCT00054665 | Trial comparisons |
| R-HCVAD/MA vs R-CHOP: Progression Free Survival (Rate) | 35 of 49 | 7 of 10 | 59 | NCT00290498 | Trial comparisons |
| RHCVAD vs RCHOP: deaths from any cause | 4 of 49 | 0 of 10 | 59 | NCT00290498 | Trial comparisons |
| RHCVAD vs RCHOP: serious adverse events | 49 of 49 | 7 of 10 | 59 | NCT00290498 | Trial comparisons |
| Phase I: Induction vs Phase II: Maintenance: serious adverse events | 3 of 19 | 1 of 29 | 48 | NCT00634179 | Trial comparisons |
| Fenretinide and Rituximab (Rituximab Naive) vs Fenretinide and Rituximab (Rituximab Pre Treated): Response Rates of B-Non-Hodgkin Lymphoma to the Combination of Rituximab and Fenretinide (Phase II) | 4 of 7 | 0 of 16 | 23 | NCT00288067 | Trial comparisons |
| MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: Number of Participants With Positive Anti-Drug Antibodies (ADA) for MEDI-551 and MEDI0680 | 1 of 5 | 0 of 5 | 10 | NCT02271945 | Trial comparisons |
| MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: deaths from any cause | 3 of 5 | 3 of 5 | 10 | NCT02271945 | Trial comparisons |
| MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg vs MEDI-551 12 mg/kg and MEDI0680 10 mg/kg: serious adverse events | 2 of 5 | 1 of 5 | 10 | NCT02271945 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015759/comparisons